How is Sculptra different from dermal fillers?

This is the most common misunderstanding about Sculptra. The volume seen immediately after treatment is mostly due to the dilution solution (such as sterile distilled water) used to dissolve the PLLA and the mild swelling from the procedure. This fluid is absorbed within a few days, so it is normal for the face to appear as if it has returned to its original state.

The actual change occurs as collagen is produced. It appears gradually over weeks to months, with noticeable changes typically starting around 2-3 months after treatment and continuing to fill in for up to 6-7 months. When and to what extent this occurs varies greatly depending on individual factors such as age, skin condition, underlying health conditions, and lifestyle habits.

Because of this time lag, it is not recommended to inject a large amount at once out of impatience. This is because the collagen response may increase later, leading to overcorrection, and the risk of side effects such as nodules also tends to increase.

First, it can fill large areas gently. It is primarily used to volumize sunken areas overall, such as the temples, the front and sides of the cheeks, and deep nasolabial folds beside the nose.

Second, because the change occurs gradually, many people who are concerned about a sudden change in appearance choose this treatment.

Third, the duration of effect is relatively long. In Europe, it was approved in 1999, and the US FDA approved it for HIV-related facial lipoatrophy in 2004 and for cosmetic indications in 2009. Accumulated literature has reported cases where the effect lasted around 2 years. However, this is an average tendency, and individual results vary. Aging also continues during this period.

Conversely, there are cases where it is not suitable. If immediate results are needed for a specific date, such as a wedding, or for areas requiring clear contouring, such as the nose or chin, dermal fillers are more appropriate.

Common reactions are similar to those of other injection treatments. Bruising and swelling at the injection site may occur for a few days and usually subside on their own, but the degree and recovery speed vary by individual.

What is particularly carefully monitored with Sculptra is delayed-onset nodules. After the procedure, weeks to months later, they are felt as small, hard lumps under the skin; many are palpable but not visible externally. About 20 years ago, in the early days of Sculptra introduction, a relatively high rate was reported, but after increasing dilution volume and establishing recommendations for injection layer and per-1-session dose, reported occurrences have significantly decreased, and recent reports indicate an incidence rate of about 0.4%. Very rarely, foreign body granulomas have also been reported.

In addition, there is a risk of infection common to all injection procedures, and, very rarely, skin necrosis or vision-related complications due to intravascular injection have also been reported. No procedure carries zero risk of side effects, so it is important to receive treatment from a Dermatologist familiar with facial anatomy and to contact them immediately if any abnormal symptoms occur.

Nodules are more likely to occur when PLLA particles clump together in one place, causing a localized excessive tissue reaction. Therefore, the key to prevention is to inject "evenly, at the appropriate depth, and in a suitable amount." The items repeatedly emphasized in the evidence-based literature are as follows.

Sufficient dilution is the first. In the early days, dilution volumes were small, but currently, for facial treatments, 8 mL or more (around 9-12 mL depending on the literature and practitioner) is commonly used. Reports of nodules have significantly decreased since dilution volumes were increased.

The second is sufficient hydration and homogeneous mixing. The PLLA must be adequately hydrated before injection and mixed evenly without sedimentation.

The third is injection depth. Superficial layers such as the dermis should be avoided; instead, it is injected into the subcutaneous fat layer or above the periosteum. The shallower the injection, the higher the risk of nodules tends to be.

The fourth is volume and interval. Avoid injecting excessive volume in a single session, and leave at least several weeks between sessions to assess the collagen response before deciding on the next session.

Lastly, areas with thin skin and a lot of muscle movement, such as around the eyes, lips, and mouth, are avoided or approached very cautiously. While these precautions can lower the risk, you should be aware that they cannot eliminate it completely.

Traditionally, the 5-5-5 principle of massaging "5 times a day, 5 minutes each time, for 5 days" has been widely recommended. The purpose is to distribute the particles so they do not clump together in one place.

However, to be precise about the evidence, this principle is a practice derived from early clinical experience and has not been proven by large-scale randomized studies. In an evaluator-blinded randomized study published in 2016, when the currently recommended dilution and injection methods were followed, no difference in nodule formation or effectiveness was observed between the group that massaged and the group that did not. However, since the study had only 20 participants and no nodules occurred in either group, it is difficult to conclude from this result alone that "massage is unnecessary."

In summary, the more decisive factors in preventing nodules are the dilution concentration, the layer of injection, the volume per session, and the interval between sessions; it is reasonable to understand massage as a low-burden auxiliary measure. Actual guidance varies depending on the dilution method used and the treatment area, so it is advisable to follow the instructions of the Dermatologist who performed the procedure.

Small nodules that are palpable but not visible often decrease over time, so the initial approach is to observe the course. If the nodule is large, visible, or accompanied by pain or redness, medical attention is needed. Depending on the Dermatologist's judgment, options include dilution by injecting saline, intralesional steroid injections, other drug injections, or, if necessary, surgical removal. However, you should be aware that most of these methods are supported only by case-level evidence, responses vary by individual, and unlike hyaluronic acid dermal fillers, there is no method to instantly dissolve and remove Sculptra.

You should inform us in advance if any of the following apply: a history of keloids or hypertrophic scars, a history of autoimmune or granulomatous diseases, active infection, inflammation, or acne in the treatment area, pregnancy or breastfeeding, use of anticoagulants, or a history of previous dermal filler treatments. In such situations, it is safe to postpone the procedure or consider alternative approaches together.

Ultimately, choosing Sculptra comes down to the question of purpose: "Do you need immediate results, or do you want gradual, broad support?" We recommend making your decision after a consultation where your individual pattern of volume loss and skin condition are assessed.